查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1927405

慢性骨髓性白血病（CML）急變期治療市場按治療類型、治療線、作用機制、給藥途徑、患者年齡層、最終用戶和配銷通路分類 - 全球預測 2026-2032

Treatment of Blastic-Phase CML Market by Treatment Type, Therapy Line, Mechanism Of Action, Route Of Administration, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，急變期慢性骨髓性白血病(CML) 治療市場價值為 7.8021 億美元，預計到 2026 年將成長至 8.6897 億美元，預計到 2032 年將達到 15.9443 億美元，複合年成長率為 10.74%。

關鍵市場統計數據
基準年 2025 7.8021億美元
預計年份：2026年 8.6897億美元
預測年份 2032 1,594,430,000 美元
複合年成長率 (%) 10.74%

本書簡明扼要、權威地介紹了慢性骨髓性白血病急變期的臨床複雜性、治療目標和治療策略。

慢性骨髓性白血病急變期是這種傳統慢性骨髓惡性腫瘤的一個嚴重且進行性的階段。其特徵是未成熟的髓系或淋巴係原始細胞快速增殖，以及臨床複雜性顯著增加。在此階段，治療目標從長期控制疾病轉變為快速細胞減滅、血液學穩定，並在可能的情況下，過渡到根治性治療，例如異體造血幹細胞移植。治療決策需要準確的分子和細胞遺傳學特徵分析、快速的多學科協作，以及在療效和耐受性之間取得合理的平衡，同時還要考慮到許多患者的體弱程度和既往治療史。

新的臨床範式、精準診斷和適應性發展策略正在重塑各種治療環境下急變期 CML 的治療和管理。

由於精準醫學的進步、分子診斷技術的改進以及對聯合治療的日益重視（旨在解決抗藥性和疾病異質性問題），慢性骨髓性白血病（CML）急變期治療格局正在發生變革性變化。標靶治療的創新拓展了傳統細胞毒性療法以外的選擇，而定序技術的進步使得早期發現新出現的抗藥性突變成為可能，從而直接指導治療順序和臨床試驗設計。同時，免疫調節策略和新型單株抗體結構的整合正在改變人們對持久疾病控制的預期，尤其是在利用互補作用機制的合理聯合治療中。

2025年美國關稅政策預期變化對急性增生期慢性骨髓性白血病治療藥物的供應鏈、採購經濟性和策略性生產選擇的影響

影響進口關稅和貿易流量的政策變化可能對腫瘤藥物的採購、定價和分銷產生重大影響，而計劃於2025年實施的關稅調整方案需要慢性粒細胞白血病（CML）急變期生態系統中的相關人員認真考慮。原料藥、生物製藥中間體或成品藥關稅的提高可能導致醫院、專科診所和藥品批發商的採購成本上升，進而可能對合約策略和預算分配造成壓力。依賴全球供應鏈採購原料藥和外包委託製造的製造商可能面臨成本上漲的壓力，這或許會迫使他們重新談判供應商合約或轉移生產。

基於深入的細分市場分析，揭示了治療類型、治療線、作用機制、給藥途徑、最終用戶和分銷管道對策略選擇的影響。

細分市場層面的洞察揭示了治療研發和商業策略應如何與臨床實際情況和醫療服務路徑相契合。根據治療類型，聯合治療、單株抗體和小分子抑制劑的市場動態各不相同。聯合治療強調協同機制和安全性管理；單株抗體需要特殊的輸注劑量和規模化生產的考量；而小分子抑制劑則受益於口服給藥和成熟的生產平台。根據治療線數，第一線、二線、三線及後續治療階段各自面臨不同的挑戰。第一線治療優先考慮耐受性和持久療效；二線治療需平衡抗藥性和先前用藥情況；而後續治療階段則著重於挽救治療和安寧療護。

區域監管環境、支付方環境和供應鏈現狀將如何影響美洲、歐洲、中東和非洲以及亞太地區的治療取得和採用趨勢

區域趨勢對慢性骨髓性白血病（CML）急變期治療的臨床實踐、支付方框架和准入途徑有顯著影響。在美洲，完善的研究基礎設施、活躍的臨床試驗網路以及多元化的公私支付方將影響治療方案的推廣應用軌跡，而供應鏈集中度和監管要求將影響商業化時間表和報銷談判。跨境貿易模式和區域製造地也將影響全部區域醫院和專科診所的籌資策略和庫存計劃。

領先的療法開發商正在推進其產品線並實現慢性骨髓性白血病（CML）急變期治療藥物的商業化，這影響著他們的企業策略、合作以及營運重點。

製藥和生物技術公司的活動將繼續圍繞差異化產品線、策略合作和營運彈性展開，以應對慢性骨髓性白血病（CML）急變期特有的挑戰。開發Bcr-Abl抑制劑的公司正在投資下一代化合物和伴隨診斷，以克服抗藥性並延長臨床療效；而免疫調節劑和單株抗體開發商則優先考慮可整合到現有治療流程中的聯合治療。與契約製造組織（CMO）和專業分銷商合作的重要性日益凸顯，以確保供應的連續性並高效擴大生物製藥的生產規模。

為開發商、供應商和支付方提供切實可行的、具有重大影響的建議，以協調慢性骨髓性白血病(CML) 急變期的臨床創新、供應彈性和獲取途徑。

產業領導者應採取一系列綜合行動，將臨床創新與實際的藥物取得和交付考量相結合。優先考慮包含分子分層、適應性檢測要素以及與監管和報銷相關人員早期溝通的研發策略，以縮短決策時間並加強證據支持。同時，應與醫院、專科診所和門診中心合作，設計反映臨床實際的商業模式，確保患者在接受治療時能夠獲得輸液基礎設施、口服藥物監測和支持性護理資源。

我們採用透明、專家主導的調查方法，結合與臨床醫生的直接對話、系統性的文獻綜合和迭代數據檢驗，確保我們獲得可操作的見解。

本分析所依據的研究融合了定性和定量調查方法，從而提供了可靠且令人信服的證據基礎。主要研究包括對臨床專家、藥屋主任、支付方和供應鏈高管進行結構化訪談，以收集關於治療決策、採購慣例和營運限制的第一手觀點。此外，也透過對同儕審查文獻、臨床試驗註冊庫和監管指導文件的系統性回顧，對臨床療效、安全性以及發展趨勢進行背景分析。

本文簡明扼要地總結了臨床、營運和策略方面對相關人員的影響，旨在幫助他們將治療進展轉化為急性期慢性骨髓性白血病(CML) 治療效果的改善。

總之，急變期慢性骨髓性白血病（CML）既帶來了巨大的臨床挑戰，也蘊藏著治療創新的巨大機會。精準診斷、新型標靶藥物和聯合治療策略的融合正在為更有效的疾病控制鋪平道路，但要充分發揮這一潛力，需要採取協作方式，解決臨床異質性、供應鏈複雜性和支付方期望等問題。相關人員必須整合可靠的證據產生、靈活的監管參與和切實可行的准入計劃，才能將科學進步轉化為病人預後的改善。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8.慢性骨髓性白血病（CML）急變期治療市場（依治療方法分類）

  • 聯合治療
  • 單株抗體
  • 小分子抑制劑

9.慢性骨髓性白血病（CML）急變期治療市場（依治療線分類）

  • 一線治療
  • 二級治療
  • 第三線及以後

第10章慢性骨髓性白血病（CML）急變期治療市場依作用機制分類

  • Bcr-Abl抑制劑
  • 化療藥物
  • 免疫調節劑

第11章慢性骨髓性白血病（CML）急變期治療市場（依給藥途徑分類）

  • 靜脈注射
  • 口服

第12章 依病患年齡層別分類的急變期慢性骨髓性白血病(CML) 治療市場

  • 成人
  • 兒童

第13章 急變異期慢性骨髓性白血病（CML）治療市場（依最終用戶分類）

  • 門診手術中心
  • 醫院
  • 專科診所

第14章慢性骨髓性白血病（CML）急變期治療市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第15章 各地區慢性骨髓性白血病（CML）急變期治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章慢性骨髓性白血病（CML）急變期治療市場（按組別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國慢性骨髓性白血病（CML）急變期治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國急變期慢性骨髓性白血病（CML）治療市場

第19章 中國急變期慢性骨髓性白血病（CML）治療市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bristol-Myers Squibb Company
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
Product Code: MRR-4F7A6D4FF3A3

The Treatment of Blastic-Phase CML Market was valued at USD 780.21 million in 2025 and is projected to grow to USD 868.97 million in 2026, with a CAGR of 10.74%, reaching USD 1,594.43 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 780.21 million
Estimated Year [2026] USD 868.97 million
Forecast Year [2032] USD 1,594.43 million
CAGR (%) 10.74%

A concise and authoritative introduction to the clinical complexity, therapeutic objectives, and strategic treatment context for blastic-phase chronic myeloid leukemia

Blastic-phase chronic myeloid leukemia represents a critical and aggressive phase of a traditionally chronic hematologic malignancy, characterized by rapid proliferation of immature myeloid or lymphoid blasts and a substantial escalation in clinical complexity. Therapeutic goals at this stage shift decisively from long-term disease management toward rapid cytoreduction, stabilization of hematologic function, and bridging patients to potentially curative interventions such as allogeneic hematopoietic stem cell transplantation where feasible. Treatment decisions require precise molecular and cytogenetic characterization, swift multidisciplinary coordination, and a pragmatic balance between efficacy and tolerability given the frailty and treatment history of many patients.

Recent years have underscored the heterogeneity within blastic-phase presentations, including variable responses to Bcr-Abl-directed therapies, emerging resistance mechanisms, and the intersection of comorbidities that influence regimen selection. Consequently, clinicians and health systems must integrate evolving diagnostic capabilities, adaptive clinical protocols, and supportive care frameworks to optimize outcomes. From a strategic perspective, pharmaceutical innovators face the dual imperatives of demonstrating clinical benefit in small, heterogeneous patient cohorts while developing practical delivery models that account for inpatient and ambulatory settings. Moving forward, harmonizing clinical evidence with operational readiness and payer expectations will be fundamental to translating therapeutic advances into measurable patient benefit.

Emerging clinical paradigms, precision diagnostics, and adaptive development strategies reshaping how blastic-phase CML is treated and managed across care settings

The therapeutic landscape for blastic-phase CML is experiencing transformative shifts driven by precision medicine advances, improved molecular diagnostics, and a growing emphasis on combination regimens that address resistance and disease heterogeneity. Innovations in targeted therapies have expanded options beyond traditional cytotoxic approaches, and improvements in sequencing technologies enable earlier detection of emergent resistance mutations that directly inform therapeutic sequencing and trial design. At the same time, the integration of immunomodulatory strategies and novel monoclonal antibody constructs has begun to alter expectations for durable disease control, particularly when used in rational combinations that exploit complementary mechanisms.

These scientific advances are paralleled by changes in clinical development and regulatory engagement. Adaptive trial designs, biomarker-stratified cohorts, and real-world evidence frameworks are increasingly leveraged to demonstrate efficacy and safety in smaller, more targeted populations. Meanwhile, health systems are adapting care pathways to accommodate oral targeted agents, outpatient infusion regimens, and enhanced supportive care services, which together influence adherence and patient experience. Taken together, these shifts underscore a broader reorientation: from single-agent, disease-centered approaches toward personalized, multimodal strategies that align molecular insights with pragmatic care delivery and value-based considerations.

How evolving United States tariff policies in 2025 could reshape supply chains, procurement economics, and strategic manufacturing choices across blastic-phase CML therapeutics

Policy changes affecting import tariffs and trade flows can materially influence the sourcing, pricing, and distribution of oncology therapeutics, and proposed tariff adjustments slated for 2025 merit careful consideration across stakeholders in the blastic-phase CML ecosystem. Increased tariffs on active pharmaceutical ingredients, biologic intermediates, or finished drug products can translate into higher procurement costs for hospitals, specialty clinics, and pharmacy distributors, which in turn may pressure contracting strategies and budget allocations. Manufacturers that rely on global supply chains for APIs or outsourced manufacturing may experience upward cost pressure that necessitates renegotiation of supplier agreements or revision of production footprints.

Moreover, altered tariff regimes can shape strategic priorities, prompting accelerated investment in domestic manufacturing capacity, nearshoring of critical production steps, or diversification of supplier networks to mitigate exposure. Health systems and payers may respond by intensifying formulary scrutiny, seeking value-based contracting arrangements, or prioritizing therapeutics with lower total cost of care profiles. For clinical programs and commercialization plans, tariff-induced uncertainties require scenario planning that accounts for procurement timelines, inventory management, and the potential need for phased launches or prioritized allocation during periods of constrained supply. In summary, the cumulative impact of tariff changes reaches beyond direct cost implications to influence supply resilience, pricing negotiations, and competitive dynamics across the treatment continuum.

Detailed segmentation-driven intelligence revealing how treatment type, therapy line, mechanism, administration route, end user and distribution channel influence strategic choices

Segment-level insights illuminate how therapeutic development and commercial strategies should be tailored to clinical realities and care delivery pathways. Based on Treatment Type, market dynamics differ across Combination Therapies, Monoclonal Antibodies, and Small Molecule Inhibitors, with combination approaches emphasizing synergistic mechanisms and safety management, monoclonal antibodies requiring specialized infusion and scale considerations, and small molecule inhibitors benefiting from oral administration and established manufacturing platforms. Based on Therapy Line, distinctive imperatives emerge across First Line, Second Line, and Third Line And Beyond, where first-line decisions prioritize tolerability and durable response, second-line selection balances resistance profiles and prior exposure, and later lines focus on salvage options and palliative control.

Based on Mechanism Of Action, therapeutic positioning varies between Bcr-Abl Inhibitors, Chemotherapy Agents, and Immunomodulators, with Bcr-Abl inhibitors targeting driver oncogenic signaling, chemotherapy agents delivering broader cytotoxic impact, and immunomodulators aiming to harness host immune responses to improve depth and durability of remission. Based on Route Of Administration, Intravenous and Oral pathways carry distinct implications for patient convenience, monitoring requirements, and site-of-care economics; oral agents can reduce inpatient resource use but demand adherence support, while intravenous therapies necessitate infusion infrastructure and may enable controlled administration of complex biologics. Based on End User, treatment delivery and procurement will differ for Ambulatory Surgical Centers, Hospitals, and Specialty Clinics as each setting maintains unique clinical capabilities, reimbursement profiles, and contracting practices. Based on Distribution Channel, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy present varied dispensing workflows, stock management priorities, and patient access modalities that influence channel strategy. Based on Patient Age Group, adults and pediatrics present distinct clinical trial design considerations, dosing strategies, and supportive care needs, underscoring the necessity for age-specific evidence generation and patient support programs.

How regional regulatory frameworks, payer landscapes, and supply chain realities across the Americas, Europe Middle East & Africa, and Asia-Pacific drive access and adoption dynamics

Regional dynamics exert a pronounced influence on clinical practice, payer frameworks, and access pathways for blastic-phase CML therapies. In the Americas, strong research infrastructures, active clinical trial networks, and a diverse mix of private and public payers shape adoption trajectories, while supply chain concentration and regulatory requirements influence commercialization timelines and reimbursement negotiations. Cross-border trade patterns and regional manufacturing hubs also affect procurement strategies and inventory planning for hospitals and specialty clinics throughout the region.

Europe, Middle East & Africa encompasses a broad spectrum of regulatory and reimbursement models, where national health technology assessment processes, centralized regulatory pathways, and variable healthcare budgets determine the pace and breadth of access. In some markets within these regions, established reference pricing and tendering mechanisms create competitive pressures that favor demonstrated value and cost-effectiveness, thereby shaping clinical adoption and local formulary decisions. Infrastructure constraints in several markets may prioritize scalable oral regimens and outpatient management strategies to maximize reach.

The Asia-Pacific region features rapid expansion of clinical research activity, increasing domestic manufacturing capacity, and a mix of mature and emerging payer systems. Rapidly growing demand for hematologic oncology care, paired with evolving reimbursement coverage and strategic public-private partnerships, positions the region as a pivotal arena for clinical trials and launch sequencing. Across all regions, local regulatory engagement, stakeholder education, and supply chain planning remain essential to achieving timely access and optimizing patient outcomes.

Corporate strategies, collaborations, and operational priorities shaping how leading therapeutic developers advance pipelines and commercialize blastic-phase CML treatments

Corporate behavior among pharmaceutical and biotechnology organizations will continue to center on pipeline differentiation, strategic partnerships, and operational agility to address the distinct challenges of blastic-phase CML. Companies advancing Bcr-Abl inhibitors are investing in next-generation compounds and companion diagnostics to overcome resistance and extend clinical durability, while developers of immunomodulatory agents and monoclonal antibodies prioritize combination regimens that can be integrated into existing treatment algorithms. Partnerships with contract manufacturing organizations and specialty distribution firms are increasingly prioritized to ensure supply continuity and to scale biologic production efficiently.

Competitive positioning also depends on strategic investments in clinical development design, including adaptive trials, biomarker-driven subgroup analyses, and expanded access initiatives that can generate early real-world evidence. Commercial strategy is informed by the need to demonstrate value to hospital systems and specialty clinics, supported by robust pharmacoeconomic evidence and targeted patient support programs that address adherence and access barriers. Ultimately, successful organizations will align scientific differentiation with pragmatic commercialization capabilities, leveraging cross-functional collaboration across clinical affairs, regulatory, market access, and supply operations to accelerate uptake and sustain long-term viability.

Actionable, high-impact recommendations for developers, providers, and payers to align clinical innovation, supply resilience, and access pathways for blastic-phase CML

Industry leaders should pursue an integrated set of actions that align clinical innovation with pragmatic access and delivery considerations. Prioritize development strategies that incorporate molecular stratification, adaptive trial elements, and early engagement with regulatory and reimbursement stakeholders to reduce time-to-decision and strengthen evidentiary packages. Simultaneously, design commercial models that reflect site-of-care realities by coordinating with hospitals, specialty clinics, and ambulatory centers to ensure that infusion infrastructure, oral therapy monitoring, and supportive care resources are available where patients receive treatment.

Invest in supply chain resilience by diversifying API and biologic sourcing, evaluating nearshoring or regional manufacturing partnerships, and enhancing inventory management systems to mitigate tariff and trade disruptions. Build payer and provider engagement programs that foreground total cost of care, real-world outcomes, and patient-reported measures to support value-based contracting and formulary inclusion. Expand patient support and adherence initiatives tailored to adult and pediatric populations to maximize therapeutic benefit, and integrate digital health solutions to monitor response and toxicities. Finally, foster cross-sector collaborations that combine diagnostic expertise, clinical networks, and commercial capabilities to accelerate uptake and ensure that therapeutic advances translate into meaningful improvements in patient care.

A transparent, expert-driven research methodology combining primary clinician engagement, systematic literature synthesis, and iterative data validation to ensure actionable insights

The research underpinning this analysis synthesizes qualitative and quantitative methodologies to provide a robust and defensible evidence base. Primary research comprises structured interviews with clinical experts, pharmacy directors, payers, and supply chain executives to capture frontline perspectives on treatment decision-making, procurement practices, and operational constraints. These insights are complemented by a systematic review of peer-reviewed literature, clinical trial registries, and regulatory guidance documents to contextualize clinical efficacy, safety profiles, and development trends.

Secondary data collection includes an assessment of published clinical outcomes, treatment guidelines, and policy analyses to inform thematic trends and treatment paradigms. Data validation is achieved through triangulation across sources and iterative review with subject matter experts to ensure consistency and practical relevance. Where appropriate, sensitivity analyses and scenario planning were employed to evaluate the implications of supply disruptions, policy shifts, and therapeutic innovation on clinical and commercial pathways. Limitations include variability in data availability for rare and heterogeneous patient subgroups and the evolving nature of clinical trial outcomes, which necessitate ongoing monitoring and periodic update cycles to maintain currency.

A concise synthesis of clinical, operational, and strategic implications for stakeholders aiming to translate therapeutic advances into improved outcomes for blastic-phase CML

In conclusion, blastic-phase CML presents both significant clinical challenges and clear opportunities for therapeutic innovation. The convergence of precision diagnostics, novel targeted agents, and combination strategies creates a pathway toward more effective disease control, but realizing this potential requires coordinated approaches that address clinical heterogeneity, supply chain complexity, and payer expectations. Stakeholders must integrate robust evidence generation, adaptive regulatory engagement, and pragmatic access planning to translate scientific advances into improved patient outcomes.

Forward-looking organizations will prioritize molecularly informed development, durable partnerships across manufacturing and distribution, and proactive payer engagement to secure access across diverse regional markets. By aligning clinical ambition with operational readiness, the field can advance beyond incremental gains and deliver tangible benefit to patients facing this aggressive phase of disease. Continuous monitoring of clinical evidence, policy shifts, and supply dynamics will remain essential to adapt strategies as new data and external conditions evolve.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Treatment of Blastic-Phase CML Market, by Treatment Type

  • 8.1. Combination Therapies
  • 8.2. Monoclonal Antibodies
  • 8.3. Small Molecule Inhibitors

9. Treatment of Blastic-Phase CML Market, by Therapy Line

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line And Beyond

10. Treatment of Blastic-Phase CML Market, by Mechanism Of Action

  • 10.1. Bcr-Abl Inhibitors
  • 10.2. Chemotherapy Agents
  • 10.3. Immunomodulators

11. Treatment of Blastic-Phase CML Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral

12. Treatment of Blastic-Phase CML Market, by Patient Age Group

  • 12.1. Adults
  • 12.2. Pediatrics

13. Treatment of Blastic-Phase CML Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Hospitals
  • 13.3. Specialty Clinics

14. Treatment of Blastic-Phase CML Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Treatment of Blastic-Phase CML Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Treatment of Blastic-Phase CML Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Treatment of Blastic-Phase CML Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Treatment of Blastic-Phase CML Market

19. China Treatment of Blastic-Phase CML Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Bristol-Myers Squibb Company
  • 20.6. Hikma Pharmaceuticals PLC
  • 20.7. Lupin Limited
  • 20.8. Novartis AG
  • 20.9. Pfizer Inc.
  • 20.10. Sandoz International GmbH
  • 20.11. Sun Pharmaceutical Industries Limited
  • 20.12. Takeda Pharmaceutical Company Limited
  • 20.13. Teva Pharmaceutical Industries Limited
  • 20.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY BCR-ABL INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY BCR-ABL INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)